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Recommended by David Allsop
Amyloid β (Aβ) annular protoﬁbrils (APFs) have been described where the structure is related to that of β barrel pore-forming
bacterial toxins and exhibits cellular toxicity. To investigate the relationship of Aβ APFs to disease and their ultrastructural
localization in brain tissue, we conducted a pre-embedding immunoelectron microscopic study using anti-annular protoﬁbril
antiserum. We examined brain tissues of young- and old-aged amyloid precursor protein transgenic mice (APP23), neprilysin
knockout APP23 mice, and nontransgenic littermates. αAPF-immunoreactions tended to be found (1) on plasma membranes and
vesicles inside of cell processes, but not on amyloid ﬁbrils, (2) with higher density due to aging, APP transgene, and neprilysin
deﬁciency, and (3) with higher positive rate at synaptic compartments in aged APP23, especially in neprilysin knockout APP23
mice. These ﬁndings imply that APFs are distinct from amyloid ﬁbrils, interact with biological membranes, and might be related
to synaptic dysfunction in Alzheimer model mouse brains.
Copyright © 2009 Hideko Kokubo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The pathologic hallmarks of Alzheimer’s disease (AD) are
accumulation of senile plaques and neuroﬁbrillaly tangles,
and loss of synapses and neurons. Amyloid beta protein (Aβ)
istheprincipalcomponentofsenileplaquesandaccumulates
in brain. In the process of accumulation, Aβ aggregates
from monomer to oligomers, protoﬁbrils or ﬁbrils. Recently,
preﬁbrillar aggregates of Aβ, such as spherical preﬁbril-
lar oligomers (PFOs) [1], Aβ-derived diﬀusible legands
(ADDLs) [2, 3] and protoﬁbrils [4–6], have been a focus of
Aβ-derived neurotoxicity [7, 8].
Dysfunction of synaptic plasticity and integrity is the
typical and early function-related event in AD [9]. Soluble
Aβ oligomers have been considered primarily responsible
for impaired synaptic plasticity and cognitive dysfunction
prior to the formation of senile plaques in transgenic
mice overexpressing human-type mutant amyloid precursor
protein (human APP Tg mouse) [10–12]. The soluble Aβ
concentration in brain shows a stronger correlation with
cognitive dysfunction [13, 14] and synapse loss [13, 15].
Aβ PFOs can assemble into annular protoﬁbrils (APFs)
[16]. APFs have been described as ring-shaped or pore-
like structures. The structure of APFs is related to that of
β barrel pore-forming bacterial toxins and exhibit cellular
toxicity, although the toxicity of APFs is less than that of
PFOs [6, 16, 17].
Neprilysin is the major Aβ-degrading enzyme in brain
and contributes to clearance of Aβ, especially oligomeric
Aβ,i nm o u s eb r a i n[ 18]. The reduced activity of neprilysin
leads to the elevation of Aβ PFOs at the synapses, and
the impaired hippocampal synaptic plasticity and cognitive2 International Journal of Alzheimer’s Disease
function [12]. Therefore, it is worthwhile to investigate
the relation between oligomeric Aβ and neprilysin to AD
pathology using human APP transgenic (Tg) mice with or
without neprilysin deﬁciency.
Previous studies on APFs were mainly conducted using
biochemical or biophysical methods, and cell culture sys-
tems. However, culture cells do not exactly reﬂect the
physiological condition in vivo, and the ultrastructural
localization of APFs in brain tissue has not yet been
demonstrated. The purpose of this study is to clarify the
ultrastructural localization of APFs in brain tissue and
its relation to Alzheimer-associated genetic modiﬁcation
using pre-embedding immunoelectron microscopy (IEM).
We used the anti-annular protoﬁbril (αAPF) antiserum [16]
and Alzheimer model Tg mice [12]. Our study ﬁrst provides
ultrastructural evidence that (1) APFs localize to plasma
membranes and vesicles inside of cell processes, (2) APFs
are on a distinct pathway from amyloid ﬁbril formation,
(3) APFs increase with aging, APP transgene, and neprilysin
deﬁciency, and (4) the synaptic compartment in aged APP
Tg mice, especially in neprilysin deﬁcient ones, shows higher
accumulation of APFs.
2.MaterialsandMethods
2.1. Animals. In this study, young (3.5–4 month-old) and
aged (17–20 month-old) APP Tg mice with human-type
APP carrying double mutations (APPK670N/M671L; APP23)
(NEP+/+APP+)[ 19], homozygous neprilysin (NEP)-deﬁci-
ent APP23 mice (NEP
−/−APP+)[ 12], and nontransgenic
(NEP+/+APP
−) littermates were used. NEP
−/−APP+ and
NEP+/+APP+ mice were produced by breeding NEP+/−APP+
and NEP+/−APP+ mice [12]. All mice were on the same
genetic background (C57BL/6J). The number of mice






−/−APP+). We examined brain samp-
les from cortical areas of the frontal lobe of each mouse.
All animal experiments were performed in compliance
with the institutional guidelines for Animal Experiments of
RIKEN. All procedures were conducted in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. All eﬀorts were made to minimize
animal suﬀering and to reduce the number of animals used.
2.2. Light and Pre-Embedding Immunoelectron Microscopy
(IEM). The mice were perfused with a ﬁxative containing
4% formaldehyde after being deeply anesthetized with
diethyl ether inhalation. For light microscopic (LM) analysis,
brain samples were immersed in the same ﬁxative, and then
embedded in paraﬃn. In order to be consistent with the IEM
procedure and to preserve the conformation of APFs, formic
acid pretreatment was not performed. For pre-embedding
IEM analysis, brain tissue blocks were immersed in the
same ﬁxative, and then cut into 40μm-thick sections with a
vibrating microtome.
The brain sections for LM and EM were incubated with
a conformation-dependent anti-annular protoﬁbril (αAPF)
antiserum (1 : 500) [16], which has been well characterized
by ELISA and Western blotting and selectively recognizes
APFs regardless of their sequence and heptameric alpha
hemolysin pores, or anti-Aβ N-terminal, aﬃnity puriﬁed
polyclonal antibody (pAb) (2μg/mL, IBL, Japan), which
recognizes the amino-terminal structure of Aβ not full-
lengthAPPandbetaC-terminalfragments(βCTFs).ForLM,
immunoreaction (IR) was visualized using a Vecstain ABC
Elite kit (Vector Lab., USA) with a diaminobenzidine (DAB).
For pre-embedding IEM, the brain sections were then
incubated with horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG (Fab’) (1 : 100, IBL, Japan), developed
with DAB solution, osmiﬁed and embedded in epoxy resin.
We tried post-embedding IEM for αAPF antiserum, but
the antiserum did not work for post-embedding IEM. On
the other hand, αP F Op A b ,A 1 1[ 1], does not work for
pre-embedding IEM. Therefore, we could not compare the
staining pattern between APF and PFO by the same method.
For control study of LM and pre-embedding IEM, the
sections were incubated with normal rabbit IgG. There was
nostainingofthesectionsincubatedwithnormalrabbitIgG.
2.3. EM Observation and Quantitative Analysis. IEM sec-
tions were observed under an electron microscope (JEOL
100CXII). We randomly took 50 photographs (ﬁelds) for
each mouse at the same magniﬁcation. The magniﬁcation
of each photo print was × 31000, and the actual size of
each ﬁeld was 2.1μm2. We counted the number of αAPF-IRs
and examined the distribution pattern of immunoreactions.
Morphological terminology is consistent with Peters et al
[20]. In addition, we counted the number of synapses in
photo prints and examined whether the synaptic compart-
ments are positive for αAPF antiserum.
3. Results and Discussion
3.1. Light Microscopy. In all age and genotypic groups of
mice, paraﬃn-embedded brain sections did not show any
immunoreactions (IRs) for αAPF antiserum (Figure 1(a)).
This is consistent with the lack of αAPF staining in human
AD brain previously reported [16]. In comparison, anti-
Aβ N-terminal, aﬃnity puriﬁed pAb (IBL, Japan) strongly
labeled senile plaques in aged NEP
−/−APP+ (Figure 1(b))
and NEP+/+APP+ mouse brain sections (data not shown).
Some punctate intracellular Aβ labeling was observed in
aged NEP
−/−APP+ and NEP+/+APP+ mouse brains (data not
shown). There was no senile plaque in young mouse and
aged non Tg mouse brains.
3.2. Ultrastructural Localization of Anti-Annular Protoﬁbril-
and Aβ N-Terminal-IRs in Mouse Brain Tissue. In young
NEP+/+APP
− mouse brains, only three anti-annular
protoﬁbril-IRs (αAPF-IRs) were observed in 150 photo
prints for three mice (50 photo prints for each mouse). This
means that young NEP+/+APP
− mice were almost negative
for APFs at least with regard to the method used in this
study. Therefore, the morphological ﬁndings mentioned
below were in young Tg and aged mouse brains.
Most of the αA P F - I R sw e r el o c a l i z e dt oc e l lp r o c e s s e si n





Figure 1: The labeling pattern of the anti-annular protoﬁbril
(αAPF) antiserum and anti-Aβ N-terminal pAb in serial sections
of aged NEP
−/−APP
+ mouse brain (embedded in paraﬃn) by
light microscopy. DAB method, 100x. Cap, capillary. (a) No
immunoreaction (IR) for αAPF antiserum was observed. (b) Anti-
Aβ N-terminal pAb strongly labeled senile plaques.
EM level. We did not measure the area of processes and cell
bodies, and did not quantitatively compare the density of
αAPF-IRs between processes and cell bodies. However, we
found less apparent αAPF-IRs inside of cell bodies during
observationbyEM.Axons,dendrites,andsmall,unidentiﬁed
processes showed αAPF-IRs (Figures 2(a), 2(b), and 2(c)).
With regard to the unidentiﬁed processes, it is assumed that
most were not glial but neuronal, due to their roundish
appearance. Most of the αA P F - I R sw e r ef o u n do np l a s m a
membranes and vesicles inside of cell processes. In synapses,
αAPF-IRs appeared on perisynaptic plasma membranes and
synaptic vesicles (Figures 2(a), and 2(d)). αAPF-positive
synapses exhibited a normal appearance. Although only a
few immunoreactions were observed, postsynaptic densities
also showed αAPF-IRs (Figure 2(d)). In aged NEP
−/−APP+
andNEP+/+APP+ mousebrainsinwhichmanysenileplaques
appeared, αAPF-IRs were not found on amyloid ﬁbrils or in
distended neurites (Figures 2(e) and 2(f)).
The immunoreactions of anti-Aβ N-terminal pAb were
f o u n do na m y l o i dﬁ b r i l si na g e dN E P
−/−APP+ (Figure 3(a))
and NEP+/+APP+ mouse brains (data not shown). Intra-
cellularly, Golgi apparatus, vesicles in the vicinity of Golgi
apparatus, lysosomes, and multivesicular bodies in neurons
were positive in young and aged, NEP
−/−APP+ (data not
shown) and NEP+/+APP+ (Figure 3(b)) mouse brains.
3.3. Quantitative Analysis of αAPF-IRs in Tg and nonTg
Mouse Brains at the EM Level. In the young group, the
number of αAPF-IRs per ﬁeld (photo print) was signiﬁcantly
greater in NEP
−/−APP+ (0.16 ± 0.40/ﬁeld; mean ± SD)
(P<. 01, Scheﬀe’s multiple test) than in NEP+/+APP
−
mouse brains (0.02 ± 0.14/ﬁeld) (Figure 4). Although the
diﬀerence between NEP+/+APP+ and NEP+/+APP
− mouse
brains did not reach the statistical signiﬁcance, NEP+/+APP+
mice showed greater number of αAPF-IRs per ﬁeld (0.11 ±
0.33/ﬁeld) than NEP+/+APP
− mice (Figure 4). In the aged
group, NEP
−/−APP+ (0.61 ± 0.80/ﬁeld) and NEP+/+APP+
mice (0.40 ± 0.69/ﬁeld) exhibited signiﬁcantly greater num-
bers of αAPF-IRs per ﬁeld than in NEP+/+APP
− mice (0.09±
0.33/ﬁeld) (P<. 01, Scheﬀe’s multiple test) (Figure 4). With
regard to the age in the same genotype, the number of αAPF-
IRs per ﬁeld was signiﬁcantly greater in aged mice than in
young mice (P<. 05 for NEP+/+APP
− mice; P<. 01 for
NEP
−/−APP+ and NEP+/+APP+ mice, Mann-Whitney’s U
test).
Next, we analyzed the distribution pattern of αAPF-
IRs, which localized to cell processes (Table 1). Although
the distribution pattern did not show statistically signiﬁcant
diﬀerence among three genotypic groups for each age (χ2
for independence test), diﬀerences in distribution among
process types were observed. In all groups of mice, many
of the total αAPF-IRs were localized to small, unidentiﬁed
processes, followed by axons. The distribution of αAPF-IRs
on axon terminals was greater in aged NEP+/+APP+ and
NEP
−/−APP+ mice than in aged NEP+/+APP
− mice. The
αAPF-IRs were not observed on axon terminals in young
mice. In addition, a few αAPF-IRs were observed on post-
synaptic process in young NEP+/+APP+ and NEP
−/−APP+
mice, and aged NEP
−/−APP+ mice.
Then, we counted the number of αAPF-positive and
-negative synapses in photo prints (Table 2). The aged
NEP
−/−APP+ and NEP+/+APP+ mice exhibited the signiﬁ-
cantly higher positive rate than that in aged NEP+/+APP
−
mice (P<. 01, χ2 for independence test).
3.4. Discussion. We have provided the ﬁrst ultrastructural
evidence that APFs interact with biological membranes in
mouse brain tissue using pre-embedding IEM. The αAPF-
IRs increased due to aging, APP transgene and neprilysin
deﬁciency. Furthermore, the data show that neprilysin
deﬁciency increased the number of APFs in the synaptic
compartment of Alzheimer model Tg mouse, especially in
NEP
−/−APP+ mouse brains.
With regard to the IEM study, the preservation of
morphology from post mortal change is particularly impor-
tant. In the pre-embedding IEM, the morphology is poor
compared to that in the post-embedding IEM. This is
because the concentration of ﬁxative is weaker in the pre-
embedding than in the post-embedding IEM. The αAPF
antiserum works only for pre-embedding IEM, not for post-
embedding IEM. Furthermore, the large post mortal change
is unavoidable in autopsied human brain due to the post
mortem interval. In order to obtain better morphology, we
did not use human brains. In addition, we examined the
inﬂuence of neprilysin on the accumulation of APFs in this
study.Forthepurposeofthisstudy,thebrainsofhumanAPP
Tg mice with or without neprilysin deﬁciency are better than
human brains. For these reasons, we did not use human AD
and control brains.
At the light microscopic level, paraﬃn-embedded brain
sections did not show any immunoreactions for αAPF anti-
serum. In addition, the result that αAPF-IRs were not found
on amyloid ﬁbrils in aged NEP
−/−APP+ and NEP+/+APP+
mouse brains at the EM level was remarkably diﬀerent






















Figure 2: Ultrastructural localization of annular protoﬁbrils (APFs) in aged NEP
+/+APP
+ (a,c) and NEP
−/−APP
+ (b,d–f) mouse brain
sections. DAB method. (a) Anti-annular protoﬁbril immunoreactions (αAPF-IRs) on synaptic vesicles in axon terminal (AT) and vesicles in
axon (Ax). Den: dendrite, Glia: glial process, and Mit: mitochondria. (b,c) αAPF-IRs on plasma membranes of dendrite (b) and unidentiﬁed
process (UN) (c). (d) αAPF-IR on postsynaptic density (PSD). (e,f) αAPF-IRs were observed on plasma membranes and vesicles inside of
cell processes (arrows) in senile plaques, but not on amyloid ﬁbrils (Fib) and distended neurites (DN). Scale bar = 200nm.
Table 1: Distribution of anti-annular protoﬁbril immunoreactions (αAPF-IRs) localized to cell processes.





− 0(0.0%)(b) 0 (0.0) 1 (33.3) 0 (0.0) 2 (66.7) 3
NEP
+/+APP
+ 3 (18.8) 0 (0.0) 1 (6.3) 1 (6.3) 11 (68.8) 16
NEP
−/−APP




− 3 (23.1) 1 (7.7) 0 (0.0) 0 (0.0) 9 (69.2) 13
NEP
+/+APP
+ 11 (18.3) 6 (10.0) 1 (1.7) 0 (0.0) 42 (70.0) 60
NEP
−/−APP
+ 16 (17.6) 12 (13.2) 2 (2.2) 5 (5.5) 56 (61.5) 91












Figure 3: Ultrastructural localization of anti-Aβ N-terminal immunoreactions (αAβ N-terminal IRs) in aged NEP
−/−APP
+ (a) and aged
NEP
+/+APP
+ (b) mouse brain sections. (a) αAβ N-terminal IRs (arrow, representative) were strongly observed on amyloid ﬁbrils in senile
plaques. Ax: axon, Den: dendrite, and AT: axon terminal. (b) Intracellular αAβ N-terminal IRs observed on Golgi apparatus (Go) and
lysosomes (Ly) in neuron. Scale bar = 200nm. Nu: nucleus, Mit: mitochondria.





− 0 (0.0%)(b) 255 (100.0) 255
NEP
+/+APP
+ 1 (0.3) 300 (99.7) 301
NEP
−/−APP




− 1 (0.4) 261 (99.6) 262
NEP
+/+APP
+ 6 (2.1) 283 (97.9) 289
NEP
−/−APP
+ 17 (5.4) 297 (94.6) 314
(a)The total number of synapses observed in 150 photo prints for each group. (b)The number and percentage of total synapses. (c)T h ep o s i t i v er a t ew a s






























Figure 4: Density of αAPF-IRs at the cell processes in mouse brain
tissue. In the young group, the density was signiﬁcantly higher
in NEP
−/−APP
+ mice than that in NEP
+/+APP
− mice (∗∗, P<
.01, Scheﬀe’s multiple test). In the aged group, the densities were







− mice (∗∗, P<. 01, Scheﬀe’s multiple test).
were recognized by A11 PFOs-speciﬁc antibody [1], and Aβ
recognized by anti-Aβ N-terminal antibody. Although the
number was few, the immunoreactions of A11-positive Aβ
PFOs were found on the periphery of amyloid ﬁbril deposits
[21, 22]. These ﬁndings suggest the diﬀerence between Aβ
PFOs and APFs in the pathways of Aβ aggregation. The
Aβ PFOs could be not only the intermediates of Aβ ﬁbril
aggregation but also the precursors for APF formation [16].
However, APFs could not be the intermediates but seem to
be on a distinct pathway from Aβ ﬁbril formation. It is not
clear that what is the determinant of the pathways for Aβ
PFOs to form whether amyloid ﬁbrils or APFs. Yamamoto et
al. [23] demonstrated that cell-surface GM1-ganglioside of
cultured neurons induces thioﬂavin-S-positive Aβ assembly.
Such GM1-ganglioside-rich membrane microdomains may
provide the platform for early stage of Aβ ﬁbril aggregation.
Many of the total αAPF-IRs were localized to small,
unidentiﬁed processes. At the subcellular level, most of the
αAPF-IRsarelocalizedtotheplasmamembranesandvesicles
inside of cell processes. In previous studies, the membrane-
bound Aβ was demonstrated as the initial deposition of
Aβ in diﬀuse plaques [24]. Furthermore, A11-positive Aβ
PFOs [12, 21, 22]a n dr a f t s[ 25] were also observed on
plasma membranes in small, unidentiﬁed processes and
organelles within cell processes. The similarity of APFs with
PFOs and rafts in the spatial terms might account for the
possibility that rafts oﬀer the sites of initial Aβ aggregation.
TheinteractionofPFOswithmembranescatalysestheircon-
formational conversion into annular protoﬁbril pores [16].6 International Journal of Alzheimer’s Disease
Oligomerization of Aβ begins intracellularly rather than
extracellularly [26, 27]. In light of these points, our ﬁndings
that the APFs interact with the biological membranes, and
αAPF-IRs were observed on plasma membranes and vesicles
inside of cell processes are reasonable.
Membrane permeabilization may represent a primary,
common mechanism of pathogenesis for amyloid diseases
[7, 28]. Lal et al. [29] suggested that the ion channels
made of small Aβ oligomers perturb cell ionic homeostasis
and exert cellular toxicity. Preformed APFs do not insert
eﬃciently when they have been formed in the absence of the
target membrane, and are signiﬁcantly less toxic than PFOs.
However, when PFOs interact with membranes, conducting
β-barrel APF pores may be able to grow and elongate by
integration of additional PFO subunits [16]. These results
may account for PFO’s ability to permeabilize membranes
and APF’s toxicity related to their ability to form membrane
permeabilizing β-barrel pores [16].
APP is axonally transported and cleaved by β-a n d
γ-secretases to produce Aβ presynaptically [30, 31]. Aβ
assembly is initiated at synaptophysin-positive site in pri-
mary neuronal cultures [23]. Several lines of evidence
have demonstrated that the soluble Aβ oligomers are pri-
mary responsible for synaptic dysfunction in the brains of
AD model Tg mice [10–12]. Neprilysin, an Aβ-degrading
enzyme, localizes to presynaptic sites and contributes to
clearance of Aβ, especially oligomeric Aβ, in mouse brain
[18]. Neprilysin is decreased in AD brain compared to
that in normal controls, and decreased neprilysin may
contribute to AD pathogenesis [32, 33]. In the current
study, we found signiﬁcantly greater numbers of αAPF-IRs
per ﬁeld, and higher positive rate of αAPF-IRs in synaptic
compartment predominate to presynaptic site in the brains
ofagedAlzheimermodelTgmice,especiallyinNEP
−/−APP+
mice than in aged NEP+/+APP
− mice. In the previous study,
neprilysin deﬁciency induced the increase of Aβ PFOs at the
synapses, especially to presynaptic site, in the hippocampus
and the dentate gyrus of 3-4 month-old NEP
−/−APP+ mice
compared to NEP+/+APP+ mice [12]. Moreover, the 3-4
month-old NEP
−/−APP+ and NEP+/+APP+ mice exhibited
the impaired hippocampal synaptic plasticity and cognitive
function before senile plaque formation [12]. On the other
hand, Lacor et al. [34, 35] demonstrated that the Aβ-
derived duﬀusible ligands (ADDLs) bound to dnedritic
spines induced aberrant spine morphology and decreased
spine density using mature hippocampal neuron cultures.
Long term potentiation (LTP), a form of synaptic plasticity,
is closely associated with postsynaptic site involving postsy-
naptic phosphorylation and glutamate receptor traﬃcking
[36, 37]. It is likely that Aβ oligomers exert their eﬀect
on postsynaptic process. The reason for the diﬀerence in
the observed pre- or post-synaptic localization, in which
the immunoreactions of preﬁbrillar aggregates of Aβ were
predominantly observed, was unclear. However, due to the
localization of neprilysin to the presynaptic site, neprilysin
deﬁciency might amplify the elevation of Aβ PFOs and
APFs at the presynaptic site. Our results indicate that Aβ
PFOs that escape degradation by neprilysin at presynaptic
site further aggregate to APFs to form pores on the plasma
membranes and membranes of vesicles within cell processes.
Such membrane pores might disturb ionic homeostasis and
exert toxicity at cell processes and synapses. The presence
of neprilysin at presynaptic site is particularly important to
protectsynapsesfromoligomer-derivedsynaptotoxicity.Our
ﬁndings further indicate the possibility that using neprilysin
activity could alleviate or improve the cognitive dysfunction
in AD by reducing oligomeric Aβ at synaptic compartment.
4. Conclusions
Inconclusion,thelocalizationofAPFstoplasmamembranes
and vesicles inside of cell processes indicates the possibility
that these are the target and/or the production site of APFs.
The increase of the positive rate of αA P F - I R sa ts y n a p t i c
compartment in aged Alzheimer model Tg mice further
supports the hypothesis that accumulation of Aβ oligomers
including PFOs and APFs in synaptic compartments results
in synaptic, cognitive dysfunction in AD. Furthermore, using
neprilysin activity may have a chance to treat the cognitive
dysfunction in AD by reducing oligomeric Aβ at synaptic
compartment.
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